Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

ChemR23 and interrupt the early steps associated with the development of psoriatic dermal inflammation and other inflammatory diseases.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN (now designated GSK1605786, also known as GSK'786), a specific CCR9 antagonist, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. Other clinical programs include CCX140, which targets the CCR2 receptor, in Phase II clinical development for the treatment of type 2 diabetes mellitus and associated complications; CCX354, a CCR1 antagonist in a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR antagonist, that completed Phase I clinical development and is anticipated to enter Phase II clinical trials in 2011; and CCX832, a ChemR23 antagonist in a Phase I clinical trial. ChemoCentryx also has several programs in advanced preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Certain statements in this pres
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... DUBLIN , Apr. 16, 2015 Research and ... addition of the "Corporate Reputation of Pharma in ... 2nd edition" report to their offering. ... perspectives from 130 patient groups with an interest in ... companies (and of the pharma industry as a whole) ...
(Date:4/17/2015)... -- Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical company focused ... the treatment of cancer and diseases of the central ... three of its most advanced oncology programs at the ... Annual Meeting being held from April 18-22, 2015 ... The presentation on the BNC105 program describes ...
(Date:4/16/2015)... , April 16, 2015  Hologic, Inc. ... cervical cancer screening study i published on-line ... peer-reviewed journal of the American Cancer Society. ... and the University of Pittsburgh Medical Center, supports current consensus ... recommend that women 30-65 years of age be ...
Breaking Medicine Technology:Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 2Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 3Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 4Bionomics Showcases Oncology Drug Development Programs at 2015 AACR Annual Meeting 5Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4
... 2011 Johnson & Johnson (NYSE: JNJ ... at a meeting with the investment community today.  Senior ... will review how the business plans to address some ... pharmaceutical market growth with an optimized product portfolio, robust ...
... May 26, 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ: ... its previously announced pipeline strategy, CTI has identified a ... candidate being investigated in the field of cancer immunotherapy. ... therapeutics activate macrophages and dendritic cells to present foreign ...
Cached Medicine Technology:Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 2Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 3Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 4Johnson & Johnson Highlights Strategies for Growth Through Differentiated Medicines, Transformational Pipeline and Global Product Launches 5CTI Provides Update on New Product Acquisition Strategy and Upcoming ASCO Events 2CTI Provides Update on New Product Acquisition Strategy and Upcoming ASCO Events 3CTI Provides Update on New Product Acquisition Strategy and Upcoming ASCO Events 4CTI Provides Update on New Product Acquisition Strategy and Upcoming ASCO Events 5
(Date:4/18/2015)... has released a new blog post explaining how to ... Clients can review important auto insurance quotes online, by ... advantages for clients who need affordable financial security for ... coverage for their vehicles can purchase a policy at ... agencies offer important discounts and drivers can learn more ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been undergoing ... to run maintenance on our shipping facilities to update ... PR Director. "It disrupted our regular shipping schedule but ... on track after having completed the maintenance." , Now, ... which has not allowed some calls to come in ...
(Date:4/18/2015)... 18, 2015 PHOENIX, ARIZONA – In ... with 11 other secure destruction professionals across the United ... (CSDS). He will now display “CSDS” as a professional ... before the National Association of Information Destruction 2015 Annual ... Grapevine, Texas. Of the 20 people who took the ...
(Date:4/17/2015)... ERGO-Pedic Products, LLC, which produces therapeutic ... products to help a broader range of people plagued ... the second most common visitors to doctors. , “The ... to help relieve sitting pain. Then, only a couple ... happy customers later, we began getting questions from those ...
(Date:4/17/2015)... April 17, 2015 From the day Dr. ... the Texas non-profit organization has empowered young people to create ... to bring fresh water and the Gospel to all ... University. Between March 17 and 27, students, faculty and staff ... Liberians with fresh water and the Good News of Jesus. ...
Breaking Medicine News(10 mins):Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:The Last Well and Liberty U’s TEN Initiative raises $21,000 to Bring Fresh Water & The Gospel to 7,000 Liberians 2
... and National Experts Address Smart Solutions to Keep Program,Accessible ... and the,Pennsylvania Medical Society hosted a panel discussion with ... Doctors in Medicare could,leave the program after scheduled pay ... harder for people in the program to find a ...
... Increasing the level of,Quitline smoking cessation services and ... way to reduce smoking rates, according to,two new ... a peer-reviewed,publication of the British Medical Journal. Both ... for Health Research in Portland,the Oregon Health Department, ...
... beyond, Typical ,Best, and ,Worst, Lists and ... Affecting the Quality of ... risks and the,quality of medical care travelers encounter can ... International Healthcare Rating,System, high standards of care go beyond ...
... Catholics for Choice Publishes Results of Four-Continent Poll Gauging,Catholic ... 29 Even in the face of an,AIDS epidemic ... to lift its ban on condoms. A new multinational ... using condoms is prolife,because it prevents the spread of ...
... in the Yale University-affiliated community health clinic was so,much ... almost be looking in a,mirror. The man was African ... in New Haven, Conn., (Photo: http://www.newscom.com/cgi-bin/prnh/20070531/DCTHFNS1 ... the man was coughing,feverish, and losing weight for no ...
... Specialty chemicals,maker Albemarle Corporation (NYSE: ALB ... referred to as DBM, methylene dibromide, or,MDB) by ... or as contracts allow., (Logo: http://www.newscom.com/cgi-bin/prnh/20050801/ALBEMARLELOGO ... to cover higher costs, in particular,higher raw material, ...
Cached Medicine News:Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2Health News:Smoking Cessation Rates Double With Intensive Counseling and Free Nicotine Replacement Therapy, Studies of 20,000 Smokers Show 2Health News:Smoking Cessation Rates Double With Intensive Counseling and Free Nicotine Replacement Therapy, Studies of 20,000 Smokers Show 3Health News:Smoking Cessation Rates Double With Intensive Counseling and Free Nicotine Replacement Therapy, Studies of 20,000 Smokers Show 4Health News:MEDEX 360m Rates the State of Global Medical Care for Travelers 2Health News:New Poll Shows Catholics Around the World Believe Good Catholics Can Use Condoms 2Health News:Take the Test, Take Control: World AIDS Day 2007 2Health News:Albemarle to Raise Prices of Dibromomethane 2
Valleylab Surgistat II generator provides exceptional performance, reliability, and safety benefits in a compact, easy to use unit....
3.2 mm Keratome, double bevel, sharp sides, ang. 1 Ea as quantity....
LigaSure system generator, bipolar only. Designed to permanently seal vessels and tissue bundles....
Microprocessor-based isolated electrosurgical generator, designed for all general surgical procedures. Unit includes the Valleylab adaptive REM system and Instant Response technology....
Medicine Products: